Today there are about 7B mobile phone worldwide and about 50,000 mobile health applications actively changing the landscape of how healthcare will be delivered in the next years. While numerous physical Micro-Electro-Mechanical Systems (MEMS)-based sensors are already integrated into smart phones, the linkage to bio-MEMS sensors remains largely untapped. The use of biomarkers has become increasingly intrinsic to the practice of medicine and clinical decision-making. Indeed, up to 70 percent of current medical decisions are made using diagnostic tests performed in traditional health care settings, using phlebotomists, remote laboratories, and delayed reporting. This inefficient flow of diagnostic information stifles arrival of exponential medicine. Likewise, for patients to actively manage their own wellness, we must surmount this gap.
To help overcome this significant barrier, the McDevitt laboratory has recently developed the Programmable Bio-Nano-Chip (p-BNC) system. This diagnostic technology combines unique chem- and bio-sensing capabilities with powerful machine learning algorithms yielding a platform to digitize biology that is capable of generating intuitive single-valued indices across several major diseases. These biomarker-driven modalities have the potential to capture diseases early before the spiral out of control. This lecture will summarize the use of these new diagnostic tools in the context of multi-parameter measurements for the areas of oral cancer adjunctive tests as well as for risk profiling of patients with cardiac heart disease. (Recent awards for the technology include: “Best Scientific Advances Award” by the Science Coalition, “Best of What's New Award” by Popular Science, “AACC Wallace H. Coulter Lectureship Award-2016”).